Healthcare influencer marketing, safe to run, fully compliant.

Every clinician creator is cross-checked against the relevant license registry: NPI (US MDs, DOs, NPs, PAs), GMC (UK doctors), NMC (UK nurses), EMA-member national boards (EU physicians), state medical boards, ABIM / ABMS specialty certification for US-board-certified physicians, DEA number validity where Rx-adjacent, and publicly available disciplinary-action records. Licensed therapists are verified through LCSW, LMFT, PhD, PsyD state registries. Pharmacists through PharmD state boards. The creator profile surfaces a verified badge with license number, specialty, issuing authority, expiry date, and any disciplinary history — so you never run a campaign with someone whose credential lapsed or was revoked.

Yes — Rx DTC is the hardest regulated-advertising workflow in marketing, and Orbitvibe is built for it. Briefs auto-insert Fair Balance (equivalent prominence of benefits and risks per 21 CFR 202.1), brief summary or the adequate-provision alternative with a clear linkable path to the full prescribing information, the FDA-required medication guide link, and contraindication / warning / precaution copy. Video briefs enforce the major-statement rule with spoken or clearly-readable risk info. Every draft routes through your MLR reviewers before outreach ever sends. This is the workflow you'd otherwise pay a specialist medical-advertising agency $50–100k a month to run.

Correct — EMA rules (Directive 2001/83/EC as amended) prohibit consumer-facing advertising of prescription medicines across almost every EU market, and MHRA applies equivalent rules in the UK. Orbitvibe auto-switches to disease-awareness framing in those jurisdictions: unbranded disease education, signs-and-symptoms content, 'talk to your doctor' language, and IFPMA / EFPIA / PhRMA / ABPI-code-compliant sponsorship disclosure — never a branded Rx mention to EU consumers. The cadence engine is jurisdiction-aware, so a US-style branded Rx brief is never even drafted for an EU creator.

Briefs route into Orbitvibe's in-app MLR review rail. Medical, legal, and regulatory reviewers each comment in-line on claim language, risk-info prominence, Fair Balance, off-label exposure, and citation accuracy. Comments resolve or reject by role, an auditable approval chain (reviewer name, timestamp, decision, rationale) preserves every step for the full retention window — 10 years for FDA-regulated content, per 21 CFR Part 11 electronic-records expectations. If you already use Veeva Vault PromoMats or Medical Review, we can export approved-content records into your existing PromoMats archive.

Orbitvibe monitors creator comment sections and DMs on sponsored posts for adverse-event signals — keyword and pattern matching on symptoms, product-experience complaints, and serious-event indicators (hospitalisation, life-threatening, death, congenital anomaly, disability). Detected signals surface to your pharmacovigilance queue for human review, with escalation paths to FDA MedWatch (US), EMA EudraVigilance (EU), MHRA Yellow Card (UK), and Health Canada CVR. Creator contracts obligate the creator to forward any direct reports they receive. This is not optional — undetected AEs in social channels are an active FDA enforcement priority.

Patient-advocate creators sharing their own health information are not HIPAA-regulated themselves — they own their own data. But the moment your brand, a provider, or a covered entity shares identifiable patient information with them, HIPAA applies. Orbitvibe enforces the firewall: no PHI ever flows from a covered-entity brand into a creator channel without a signed authorisation per 45 CFR 164.508, and the platform surfaces whether a given campaign touches a covered entity (hospital, health plan, covered provider) versus a non-covered brand (pharma, medtech, insurtech, DTC digital-health). Patient-story review templates also check for incidental third-party PHI exposure (family members in photos, overheard conversations in videos).

Off-label promotion is one of the most expensive mistakes in pharma — multi-billion-dollar FDA and DOJ settlements have been triggered by exactly this. Orbitvibe maintains the on-label indication set per SKU, pre-loads the creator brief with approved-use language only, and blocks risky phrasing at the brief-drafting step: no suggested uses outside the label, no dose or duration outside the label, no patient population outside the label. Creator contracts contractually obligate the creator to edit or remove off-label content. Comment monitoring also flags follower questions that might pull the creator into off-label territory, with pre-drafted on-label response templates.

Depends on what the campaign does. Marketing a hospital's brand, service lines, or physician network does not trigger IRB review. Campaigns that collect identifiable patient-outcome data, run a structured prospective observation, or cross into research activity can trigger IRB oversight under the Common Rule (45 CFR 46). Orbitvibe flags campaigns that drift toward research — patient-outcome tracking, structured comparative content, collection of sensitive patient data — and routes them to your IRB and research-compliance team before they launch. Institutional-approval disclosure language and physician-endorsement boundary rules (ABIM, AMA, state medical board) are pre-loaded for hospital and health-system briefs.

Medical tourism is the worst jurisdictional knot in healthcare marketing: a clinic in Turkey or Thailand marketing a procedure to a US or UK patient, with a creator audience spread across ten countries, each with its own consumer-health advertising rules. Orbitvibe maps the creator's audience by country, then applies the strictest-applicable-rule principle across the overlapping regulatory surfaces — US FTC substantiation and FDA device-claim rules for any US audience share, MHRA / ASA rules for UK, EMA and national-competent-authority rules for EU member states, and local accreditation claims (JCI, ISO, TEMOS) that can actually be substantiated in every market the audience sits in. You end up with creative that survives the most regulated jurisdiction the audience touches, which is typically the one that matters.

Traditional healthcare marketing splits across four line items: a specialist medical-advertising agency ($50–100k/month, Rx DTC copy and MLR coordination), a medical-affairs PR firm ($30–60k/month, KOL engagement and congress presence), an in-house creator / influencer team (6–12 people), and a regulatory-compliance headcount layer (4–8 people spanning PV, MLR coordination, Sunshine Act / EFPIA reporting). Orbitvibe consolidates every one of those workflows — clinician sourcing, license verification, MLR-integrated brief generation, jurisdiction-aware outreach, adverse-event capture, Sunshine Act transfer-of-value logging, 10-year contract archiving — into one platform run by 2 people. Typically 50–70% cheaper on fully-loaded spend with a shorter, auditable compliance trail.